Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the breast cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of pharmacy and medical benefits.
Subscribe to:
Post Comments (Atom)
< + > Healthcare IT Failures – Healthcare IT Today Podcast Episode 195
For the 195th episode of the Healthcare IT Today Podcast , we are taking a look at healthcare IT failures! We kick this episode off by debat...
No comments:
Post a Comment